
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1739025/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Data-driven cognitive phenotypes in subjects with bipolar disorder and their clinical markers of severity. Psychological Medicine, 2022, 52, 1728-1735.	4.5	7
2	The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses. Psychological Medicine, 2022, 52, 526-537.	4.5	17
3	Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers. Biochemical Pharmacology, 2022, 198, 114963.	4.4	15
4	Potential Candidates for Biomarkers in Bipolar Disorder: A Proteomic Approach through Systems Biology. Clinical Psychopharmacology and Neuroscience, 2022, 20, 211-227.	2.0	10
5	Investigation of blood-brain barrier disruption in an animal model of mania induced by D-amphetamine. Journal of Affective Disorders Reports, 2022, 9, 100368.	1.7	1
6	The assessment of lifestyle changes during the COVID-19 pandemic using a multidimensional scale. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 16-26.	1.8	118
7	COVID-19 and mental health in Brazil: Psychiatric symptoms in the general population. Journal of Psychiatric Research, 2021, 132, 32-37.	3.1	156
8	Effects of the COVID-19 pandemic and lockdown in Spain: comparison between community controls and patients with a psychiatric disorder. Preliminary results from the BRIS-MHC STUDY Journal of Affective Disorders, 2021, 281, 13-23.	4.1	70
9	Resilience and mental health during the COVID-19 pandemic. Journal of Affective Disorders, 2021, 283, 156-164.	4.1	98
10	The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholds. European Neuropsychopharmacology, 2021, 47, 98-111.	0.7	21
11	The costs of coping: Different strategies to deal with social defeat stress might come with distinct immunologic, neuroplastic, and oxidative stress consequences in male Wistar rats Behavioral Neuroscience, 2021, 135, 654-667.	1.2	3
12	Cognitive clusters in first-episode psychosis. Schizophrenia Research, 2021, 237, 31-39.	2.0	10
13	Editorial: The Role of Resilience and the Interplay Between Genetics and Environment in Bipolar Disorder. Frontiers in Psychiatry, 2021, 12, 761384.	2.6	0
14	BDNF prevents central oxidative damage in a chronic unpredictable mild stress model: The possible role of PRDX-1 in anhedonic behavior. Behavioural Brain Research, 2020, 378, 112245.	2.2	20
15	Reduction of hippocampal IL-6 levels in LPS-injected rats following acute exendin-4 treatment. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1303-1311.	3.0	3
16	A prospective longitudinal study searching for predictors of response to group psychoeducation in bipolar disorder. Journal of Affective Disorders, 2020, 274, 1113-1121.	4.1	12
17	Anhedonic-like behavior correlates with IFNÎ ³ serum levels in a two-hit model of depression. Behavioural Brain Research, 2019, 373, 112076.	2.2	19
18	Attenuated inflammatory response of monocyte-derived macrophage from patients with BD: a preliminary report. International Journal of Bipolar Disorders, 2019, 7, 13.	2.2	16

#	Article	IF	CITATIONS
19	Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability. Journal of Clinical Medicine, 2019, 8, 586.	2.4	31
20	Functional remediation improves bipolar disorder functioning with no effects on brain-derived neurotrophic factor levels. European Neuropsychopharmacology, 2019, 29, 701-710.	0.7	10
21	Perceived childhood adversities: Impact of childhood trauma to estimated intellectual functioning of individuals with bipolar disorder. Psychiatry Research, 2019, 274, 345-351.	3.3	14
22	Effects of deep breathing in patients with bipolar disorder. Perspectives in Psychiatric Care, 2019, 55, 119-125.	1.9	8
23	Identifying cognitive subgroups in bipolar disorder: A cluster analysis. Journal of Affective Disorders, 2019, 246, 252-261.	4.1	49
24	Depression and Mania Induce Pro-inflammatory Activation of Macrophages Following Application of Serum from Individuals with Bipolar Disorder. Clinical Psychopharmacology and Neuroscience, 2018, 16, 103-108.	2.0	23
25	Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0. Frontiers in Psychiatry, 2018, 9, 641.	2.6	79
26	Validity and reliability of the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) in Brazilian bipolar patients. Trends in Psychiatry and Psychotherapy, 2018, 40, 170-178.	0.8	17
27	Thresholds for severity, remission and recovery using the functioning assessment short test (FAST) in bipolar disorder. Journal of Affective Disorders, 2018, 240, 57-62.	4.1	72
28	Validation of the Korean Version of the Biological Rhythms Interview of Assessment in Neuropsychiatry. Psychiatry Investigation, 2018, 15, 1115-1120.	1.6	14
29	Hippocampal neurochemical markers in bipolar disorder patients following the first-manic episode: A prospective 12-month proton magnetic resonance spectroscopy study. Australian and New Zealand Journal of Psychiatry, 2017, 51, 65-74.	2.3	9
30	Peripheral insulin-like growth factor 1 in bipolar disorder. Psychiatry Research, 2017, 250, 30-34.	3.3	15
31	Telomere Length, Oxidative Stress, Inflammation and BDNF Levels in Siblings of Patients with Bipolar Disorder: Implications for Accelerated Cellular Aging. International Journal of Neuropsychopharmacology, 2017, 20, 445-454.	2.1	67
32	Functional Impairment in Older Adults With Bipolar Disorder. Journal of Nervous and Mental Disease, 2017, 205, 443-447.	1.0	19
33	Social cognition and bipolar disorder: A preliminary study. European Psychiatry, 2017, 41, S425-S425.	0.2	1
34	Social cognition and bipolar disorder: A preliminary study. European Psychiatry, 2017, 41, S426-S426.	0.2	0
35	Serum of Bipolar Patients Induces Pro-inflammatory Activation of Macrophages. European Psychiatry, 2017, 41, S114-S114.	0.2	0
36	Cell therapy in the treatment of bipolar mania in an animal model: a proof of concept study. Trends in Psychiatry and Psychotherapy, 2017, 39, 196-201.	0.8	2

#	Article	IF	CITATIONS
37	Analyzing leukocyte telomere length in bipolar disorder: Authors' reply. Revista Brasileira De Psiquiatria, 2017, 39, 275-276.	1.7	1
38	Cognitive performance and psychosocial functioning in patients with bipolar disorder, unaffected siblings, and healthy controls. Revista Brasileira De Psiquiatria, 2016, 38, 275-280.	1.7	12
39	Challenges and developments in research of the early stages of bipolar disorder. Revista Brasileira De Psiquiatria, 2016, 38, 329-337.	1.7	10
40	Shortened telomere length in bipolar disorder: a comparison of the early and late stages of disease. Revista Brasileira De Psiquiatria, 2016, 38, 281-286.	1.7	43
41	Cognition and functioning in bipolar depression. Revista Brasileira De Psiquiatria, 2016, 38, 201-206.	1.7	22
42	The association between biological rhythms, depression, and functioning in bipolar disorder: a large multiâ€center study. Acta Psychiatrica Scandinavica, 2016, 133, 102-108.	4.5	66
43	Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life. Acta Psychiatrica Scandinavica, 2016, 133, 386-398.	4.5	103
44	The role of macrophage polarization on bipolar disorder: Identifying new therapeutic targets. Australian and New Zealand Journal of Psychiatry, 2016, 50, 618-630.	2.3	28
45	A report on olderâ€age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disorders, 2015, 17, 689-704.	1.9	210
46	Pharmacological treatment and staging in bipolar disorder: evidence from clinical practice. Revista Brasileira De Psiquiatria, 2015, 37, 121-125.	1.7	19
47	Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders. Anais Da Academia Brasileira De Ciencias, 2015, 87, 1435-1449.	0.8	27
48	Damageâ€associated molecular patterns and immune activation in bipolar disorder. Acta Psychiatrica Scandinavica, 2015, 132, 211-217.	4.5	41
49	Verbal episodic memory along the course of schizophrenia and bipolar disorder: A new perspective. European Neuropsychopharmacology, 2015, 25, 169-175.	0.7	31
50	Treatment delay is associated with more episodes and more severe illness staging progression in patients with bipolar disorder. Psychiatry Research, 2015, 227, 372-373.	3.3	11
51	e-HCL-32: a useful, valid and user friendly tool in the screening of bipolar II disorder. Comprehensive Psychiatry, 2015, 56, 283-288.	3.1	9
52	Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychological Medicine, 2014, 44, 2409-2418.	4.5	64
53	Staging bipolar disorder: clinical, biochemical, and functional correlates. Acta Psychiatrica Scandinavica, 2014, 129, 437-444.	4.5	84
54	P.2.d.033 Staging bipolar disorder: biological, clinical and functional correlates. European Neuropsychopharmacology, 2014, 24, S432-S433.	0.7	0

#	Article	IF	CITATIONS
55	P.2.c.005 Use of mesenchymal stem cells as a novel treatment for bipolar disorder: preliminary results of an in vitro study. European Neuropsychopharmacology, 2014, 24, S410.	0.7	0
56	Functioning Assessment Short Test (FAST): validity and reliability in adults with attention-deficit/hyperactivity disorder. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 719-727.	3.2	16
57	Progesterone and its metabolites as therapeutic targets in psychiatric disorders. Expert Opinion on Therapeutic Targets, 2014, 18, 679-690.	3.4	25
58	Bipolar disorder in the elderly: a cohort study comparing older and younger patients. Acta Psychiatrica Scandinavica, 2014, 130, 364-373.	4.5	43
59	Clinical Staging in Bipolar Disorder. Journal of Clinical Psychiatry, 2014, 75, e450-e456.	2.2	125
60	Impaired endoplasmic reticulum stress response in bipolar disorder: cellular evidence of illness progression. International Journal of Neuropsychopharmacology, 2014, 17, 1453-1463.	2.1	58
61	A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. International Journal of Neuropsychopharmacology, 2013, 16, 485-496.	2.1	41
62	Biological rhythm disturbance in remitted bipolar patients. International Journal of Bipolar Disorders, 2013, 1, 6.	2.2	43
63	P.2.d.028 Relating mood to plasma glutathione and BDNF levels in patients with bipolar disorder. European Neuropsychopharmacology, 2013, 23, S380.	0.7	0
64	Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). Journal of Affective Disorders, 2013, 150, 29-36.	4.1	116
65	Peripheral toxicity in crack cocaine use disorders. Neuroscience Letters, 2013, 544, 80-84.	2.1	51
66	The Clinical Implications Of Cognitive Impairment and Allostatic Load in Bipolar Disorder. European Psychiatry, 2013, 28, 21-29.	0.2	119
67	Efficacy of Functional Remediation in Bipolar Disorder: A Multicenter Randomized Controlled Study. American Journal of Psychiatry, 2013, 170, 852-859.	7.2	269
68	Bipolar Disorder Affects Behavior and Social Skills on the Internet. PLoS ONE, 2013, 8, e79673.	2.5	11
69	Impairment in psychosocial functioning in patients with different subtypes of eating disorders. Trends in Psychiatry and Psychotherapy, 2013, 35, 111-118.	0.8	4
70	Relating mood to plasma glutathione and BDNF levels in patients with bipolar disorder. FASEB Journal, 2013, 27, lb528.	0.5	0
71	P.2.e.027 Interleukin-6 as a biomarker of the model of staging in bipolar disorder. European Neuropsychopharmacology, 2012, 22, S291-S292.	0.7	0
72	Concurrent Validity and Reliability of the Brazilian Version of the Functioning Assessment Short Test in Patients with Schizophrenia. Value in Health Regional Issues, 2012, 1, 244-247.	1.2	14

#	Article	IF	CITATIONS
73	Subthreshold symptoms in bipolar disorder: Impact on neurocognition, quality of life and disability. Journal of Affective Disorders, 2012, 136, 650-659.	4.1	156
74	Impulsivity and functional impairment in bipolar disorder. Journal of Affective Disorders, 2012, 136, 491-497.	4.1	47
75	Oneâ€year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatrica Scandinavica, 2012, 125, 335-341.	4.5	141
76	Long-Term Outcome of Cognitive Impairment in Bipolar Disorder. Journal of Clinical Psychiatry, 2012, 73, e899-e905.	2.2	143
77	Is Anticonvulsant Treatment of Mania a Class Effect? Data from Randomized Clinical Trials. CNS Neuroscience and Therapeutics, 2011, 17, 167-177.	3.9	31
78	P.2.e.002 Risk factors for antidepressant-related switch to mania. European Neuropsychopharmacology, 2011, 21, S418.	0.7	0
79	Factors associated with initial treatment response with antidepressants in bipolar disorder. European Neuropsychopharmacology, 2011, 21, 362-369.	0.7	31
80	Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. Bipolar Disorders, 2011, 13, 145-154.	1.9	62
81	Sixâ€month functional outcome of a bipolar disorder cohort in the context of a specializedâ€care program. Bipolar Disorders, 2011, 13, 679-686.	1.9	67
82	Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. Journal of Affective Disorders, 2011, 129, 321-326.	4.1	49
83	Stigma and functioning in patients with bipolar disorder. Journal of Affective Disorders, 2011, 130, 323-327.	4.1	70
84	Gender differences in a cohort study of 604 bipolar patients: The role of predominant polarity. Journal of Affective Disorders, 2011, 133, 443-449.	4.1	149
85	Staging Bipolar Disorder. Neurotoxicity Research, 2011, 19, 279-285.	2.7	100
86	Functional Remediation for Bipolar Disorder. Clinical Practice and Epidemiology in Mental Health, 2011, 7, 112-116.	1.2	82
87	Validation and Use of the Functioning Assessment Short Test in First Psychotic Episodes. Journal of Nervous and Mental Disease, 2010, 198, 836-840.	1.0	37
88	Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: A long-term, follow-up study. Journal of Affective Disorders, 2010, 121, 156-160.	4.1	273
89	The impact of staging bipolar disorder on treatment outcome of family psychoeducation. Journal of Affective Disorders, 2010, 123, 81-86.	4.1	101
90	Functional impairment in bipolar II disorder: Is it as disabling as bipolar I?. Journal of Affective Disorders, 2010, 127, 71-76.	4.1	75

#	Article	IF	CITATIONS
91	Functional Impairment and Disability across Mood States in Bipolar Disorder. Value in Health, 2010, 13, 984-988.	0.3	161
92	Has number of previous episodes any effect on response to group psychoeducation in bipolar patients? A 5-year follow-up <i>post hoc</i> analysis. Acta Neuropsychiatrica, 2010, 22, 50-53.	2.1	81
93	Why Do Clinicians Maintain Antidepressants in Some Patients With Acute Mania?. Journal of Clinical Psychiatry, 2010, 71, 1000-1006.	2.2	43
94	Bipolar disorder and age-related functional impairment. Revista Brasileira De Psiquiatria, 2009, 31, 354-357.	1.7	18
95	Development and use of a biological rhythm interview. Journal of Affective Disorders, 2009, 118, 161-165.	4.1	117
96	Predominant polarity and temperament in bipolar and unipolar affective disorders. Journal of Affective Disorders, 2009, 119, 28-33.	4.1	68
97	Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disorders, 2009, 11, 401-409.	1.9	156
98	Validity of a Short Functioning Test (FAST) in Brazilian Outpatients with Bipolar Disorder. Value in Health, 2009, 12, 624-627.	0.3	65
99	Predictores clÃnicos del funcionamiento interpersonal en pacientes bipolares. Revista De PsiquiatrÃa Y Salud Mental, 2009, 2, 83-88.	1.8	26
100	Clinical predictors of interpersonal functioning in patients with bipolar disorder. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2009, 2, 83-88.	0.3	3
101	P.3.16 Impulsivity in bipolar disorder: a randomized clinical trial of adjunctive oxcarbazepine. European Neuropsychopharmacology, 2009, 19, S75-S76.	0.7	3
102	Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatrica Scandinavica, 2008, 118, 4-18.	4.5	151
103	Functional impairment and previous suicide attempts in bipolar disorder. Acta Neuropsychiatrica, 2008, 20, 300-306.	2.1	14
104	Predominant polarity in bipolar disorder: Diagnostic implications. Journal of Affective Disorders, 2008, 107, 45-51.	4.1	98
105	Ziprasidone in the Treatment of Affective Disorders: A Review. CNS Neuroscience and Therapeutics, 2008, 14, 278-286.	3.9	23
106	Functional Impairment in Patients with Remitted Bipolar Disorder. Psychotherapy and Psychosomatics, 2008, 77, 390-392.	8.8	68
107	A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World Journal of Biological Psychiatry, 2008, 9, 219-224.	2.6	47
108	Cognitive impairment in a Brazilian sample of patients with bipolar disorder. Revista Brasileira De Psiquiatria, 2008, 30, 209-214.	1.7	9

#	Article	IF	CITATIONS
109	Evolving trends in the long-term treatment of bipolar disorder. World Journal of Biological Psychiatry, 2007, 8, 4-11.	2.6	49
110	Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clinical Practice and Epidemiology in Mental Health, 2007, 3, 5.	1.2	605
111	Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 217-224.	4.8	80
112	Serum S100B and antioxidant enzymes in bipolar patients. Journal of Psychiatric Research, 2007, 41, 523-529.	3.1	269
113	Polypharmacy and suicide attempts in bipolar disorder. Revista Brasileira De Psiquiatria, 2007, 29, 35-38.	1.7	14
114	Polypharmacy and suicide attempts in bipolar disorder. Revista Brasileira De Psiquiatria, 2007, 29, 35-8.	1.7	3
115	Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neuroscience Letters, 2006, 398, 215-219.	2.1	343
116	Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neuroscience Letters, 2006, 407, 146-150.	2.1	84
117	Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania. Behavioural Pharmacology, 2006, 17, 311-318.	1.7	41
118	Adaptation and validation of the Portuguese version of the Lithium Knowledge Test (LKT) of bipolar patients treated with lithium: cross-over study. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 34.	1.2	3
119	Validation of the Portuguese version of the Lithium Attitudes Questionnaire (LAQ) in bipolar patients treated with lithium: cross-over study. Clinical Practice and Epidemiology in Mental Health, 2006, 2,	1.2	5